Universal Health Literacy Precautions Are Associated With a Significant Increase in Medication Adherence in Vulnerable Rheumatology Patients

Joel Hirsh,1 Patrick Wood,2 Angela Keniston,3 Dennis Boyle,4 Itziar Quinzanos,5 Liron Caplan,6 and Lisa Davis7,∗

Objective. Our objective was to determine the impact of the Health Literacy Universal Precautions Toolkit, adapted for rheumatology, on medication adherence, patient satisfaction, and feasibility in all patients; its effect on the clinical disease activity index (CDAI) was studied in a rheumatoid arthritis (RA) subpopulation.

Methods. Data collected during a 6-month prospective quality assurance intervention was compared with data from a prior 6-month period. Interventions included 1) encouraging questions, 2) teach-back communication, and 3) brown-bag medication review. Analysis was performed using linear regression or generalized estimating equation (GEE) regression.

Results. During the intervention period, 46 physicians completed 1737 patient visits. Questions were encouraged, and teach-back communication was performed in more than 90% of visits. Brown-bag medication reviews were performed in 47% of visits overall and 69% of visits in a subgroup that received additional reminder calls. Visit duration and patient satisfaction were not significantly increased. Adherence for rheumatology-related medications that were prescribed both before and during the intervention increased by 22% (P ≤ 0.001; by GEE). Teach-back communication predicted a statistically significant improvement in medication adherence in this subpopulation (by linear regression). The mean CDAI did not improve; however, African American race and Hispanic ethnicity were associated with a decreased CDAI (by GEE).

Conclusion. Implementation of the Health Literacy Universal Precautions Toolkit, adapted for rheumatology, improved medication adherence in our safety-net clinic, with particularly strong effects seen with teach-back communication. In certain populations, use of the toolkit may also improve RA disease activity. This is the first study to document improved medication adherence with this intervention in a real-world setting.

INTRODUCTION

Health literacy (HL) is “the degree to which an individual has the capacity to obtain, communicate, process, and understand health information and services in order to make appropriate health care decisions” (1). A complimentary conceptualization of HL considers the health care system’s complexity (2). Nearly half of the adults in the United States have limited health literacy (LHL); LHL is more prevalent among ethnic minorities and the elderly (3). LHL is associated with poor outcomes in many chronic diseases, including rheumatoid arthritis (RA) (4).

Causal pathways proposed to explain LHL’s impact on patient outcomes include access to and use of health care, patient-provider interaction, and self-care (5). This model is supported by research illustrating the association of LHL with many factors related to these mechanisms in patients with RA (4,6–9).
The interventions proposed to mitigate the negative effects of LHL address these pathways through the use of easier-to-understand written communication, health education sessions, patient-decision aids, patient-centered communication, active listening, teach-back, and enhanced shared decision-making (13). Although improving the process and outcomes of care of patients with RA with LHL is a priority (14,15), only two studies illustrate interventions successful in this regard (16,17).

The Health Literacy Universal Precautions Toolkit was designed to combat LHL’s deleterious effects (18). The premise of HL “universal precautions” is that health care providers should deliver care under the assumption that the HL burdens of the health care system exceed the HL skills of every patient (19). This strategy is thought to be more effective over targeted interventions because not only is it challenging to identify which patients have LHL (20) but screening for LHL is also controversial given the propensity of such screening to elicit shame or embarrassment (21). The Health Literacy Universal Precautions Toolkit has been adapted for rheumatology practice (to be referred to as “toolkit” hereafter), including an abbreviated version that consists of three interventions: 1) encouraging questions, 2) the teach-back method of communication (to be referred to as “teach-back” hereafter), and 3) brown-bag medication review (22,23). The toolkit has been shown to raise provider awareness regarding LHL. No data exist regarding the feasibility of adopting the toolkit or its effects on patient satisfaction, medication adherence, RA disease activity, or concordance between patients’ and providers’ assessments of RA disease activity.

We implemented the toolkit at every visit with every patient during a 6-month intervention to examine its effect on several key domains. Our hypothesis was that its implementation would improve patient satisfaction, reduce discrepancies between the patient global assessments (PGAs) and evaluator global assessments (EGAs), improve medication adherence, and improve RA disease activity. We also measured effects on visit duration to determine the feasibility of the toolkit’s adoption in routine clinical settings.
for example, “What are you going to tell your family when you get home about what we discussed today?” Clerks who made appointment reminder calls as a matter of regular clinic flow also gave scripted instructions to patients to bring in all of their medications, supplements, and vitamins to their next appointment for a brown-bag medication review. When care of a patient included a resident physician, the attending physician performed the brown-bag medication review.

To encourage patient participation in the brown-bag medication review, signs were posted in English and Spanish in the waiting area and in the patient rooms, encouraging patients to bring their medications for review. In a convenience sample of select clinics, a bilingual research assistant performed additional reminder calls two days prior to patients’ visits to remind patients to bring in medications for the brown-bag medication review.

Preintervention data were collected between October 1, 2016, and March 31, 2017. The wash-in period began April 1, 2017. This period was intended to last 3 months; however, because of the relatively low numbers of brown-bag medication reviews being performed, the wash-in period was extended to September 30, 2017. The intervention period was October 1, 2017, to March 31, 2018. This quality improvement project was reviewed by the local institutional review board and determined to be “not human subject research.”

**Outcomes.** The primary outcome measures of this prospective quality assurance study were 1) patient satisfaction, 2) medication adherence, and, in patients with RA, 3) CDAI. A secondary outcome included any change in the mean visit duration attributable to the clinical interventions.

**Data sources and measurements.** The individual interventions that composed the toolkit were recorded in a multiresponse drop-down menu designed into the clinic’s EMR template. Physicians recorded whether they encouraged questions, used teach-back, and performed a brown-bag medication review. Patient demographics, including age, sex, ethnicity, preferred language, RA disease duration, RA disease activity measures, and insurance were derived from the EMR.

Patient satisfaction was measured though rheumatology patient experience metrics by Press Ganey and was reported to Denver Health on a monthly basis as the “top-box” percentage and “top-box” percentile rank, comparing the intervention clinic with other academic rheumatology facilities.

Medication adherence was determined through rheumatology-related medications filled at the study-site pharmacy by calculating the PDC. This measure assesses the number of days in an observation period in which a patient has the medication in his or her possession. Medications considered to be rheumatology-related included 1) synthetic disease-modifying antirheumatic drugs (sDMARDs) (azathioprine, hydroxychloroquine, leflunomide, mercaptopurine, methotrexate, mycophenolate mofetil, mycophenolate sodium, and sulfasalazine), 2) targeted and biologic disease-modifying antirheumatic drugs (bDMARDs) (abatacept, adalimumab, anakinra, apremilast, certolizumab pegol, etanercept, ixekizumab, secukinumab, tocilizumab, tofacitinib, and ustekinumab), 3) gout medications (allopurinol and febuxostat), 4) osteoporosis medications (alendronate, denosumab, and teriparatide), and 5) corticosteroids (dexamethasone, methylprednisolone, prednisolone, and prednisone). This methodology excluded medications filled outside of study-site pharmacies (such as medications administered in or filled through infusion centers, medication assistance programs, and private pharmacies) and “as-needed” medications.

RA disease activity was assessed by the CDAI, which is composed of the PGA, EGA, tender joint count, and swollen joint count (24). All joint counts were performed by attending rheumatologists or fellow rheumatologists in the normal care of their patients with RA. These measures are routinely recorded in the study-site EMR for patients with RA.

For the feasibility outcome measure, a study assistant measured the duration of new patient and return patient visits for two providers on a convenience sample of seven clinics before the intervention and seven clinics during the intervention. Each sampling of seven clinics occurred over a 6-week period during the pre- and during-intervention periods.

Data recorded in the EMR were stored in the Denver Health Data Warehouse and subsequently extracted using Structured Query Language.

**Analysis.** Statistical analyses were performed using Stata 14.2 (StataCorp). Summary data were analyzed using t test, paired t test, χ² test, or Hotelling’s T² test when appropriate. PDC was analyzed using the Stata add-on module by Linden (25). Linear regressions were used when appropriate. Generalized estimating equation (GEE) regression compared the per-patient first observation in the preintervention period with the last observation in the intervention period. Our planned analyses in the general rheumatology population included 1) demographics of the physician participants and the patients seen in the visits, 2) a report of implementation of the interventions, 3) the average PDC compared between the pre- and during-intervention periods, 4) a subanalysis of the PDC of individuals who were in both the pre- and during-intervention periods and were on the same medication in both periods, 5) characteristics and interventions associated with changes in the PDC by linear regression, and 6) patient satisfaction.

Our planned analyses of individuals with RA included 1) reports of disease activity measures in individuals with RA who were in both time periods, 2) reports of CDAl values and association with different clinical variables, 3) characteristics of interventions associated with changes in absolute value difference between PGAs and physician global assessments by GEE, and 4) characteristics of interventions associated with changes in the CDAI.
RESULTS

Demographics, visits, and interventions. During the entire observation time period (October 1, 2016, through March 31, 2018), a total of 99 physicians were observed, including 18 attending physicians, 8 fellows, and 73 residents, across a total of 5032 patient visits. During the preintervention period (October 1, 2016, through March 31, 2017), there were 14 attending physicians, 4 fellows, and 25 residents observed in 1584 visits (33%). During the wash-in period (April 1, 2017, through September 30, 2017), there were 12 attending physicians, 8 fellows, and 26 residents observed in 1711 visits (34%). During the intervention period (October 1, 2017 to March 31, 2018), there were 13 attending physicians, 5 fellows, and 28 residents observed in 1737 visits (35%) (Table 1).

Although counts of visit types (new patient versus return patient visit) did differ ($P = 0.016$), sociodemographic variables did not differ significantly between the pre- and during-intervention periods (Table 1). In the preintervention period, question encouragement, teach-back, and brown-bag medication reviews were documented in 66%, 17%, and 7% of visits, respectively. During the intervention, question encouragement, teach-back, and brown-bag medication reviews were documented in 98%, 92%, and 47% of visits, respectively. Question encouragement and brown-bag medication reviews were documented significantly more often among patients who received additional reminder calls during the intervention phase ($n = 585$) compared with patients who did not ($n = 1152$) (Table 2).

Patient satisfaction. Pre- and during-intervention patient satisfaction metrics did not statistically differ, although a nonsignificant trend toward improvement in patient satisfaction was seen regarding instruments assessing patient perception of provider instructions (Supplemental Table 1).

Medication adherence. During the entire observation period, data were collected regarding 2306 prescriptions for unique medications prescribed to 886 individuals. Four-hundred twenty-two unique prescriptions were filled during the preimplementation period only; 406 were filled only during the wash-in period; 926 were filled only during the intervention period; 552 prescriptions in which the same medication was prescribed to the same individual were filled during both the preimplementation and implementation periods. Of these 2306 prescriptions, 926 (40%) were for sDMARDs, 274 (12%)

### Table 1. Physician and patient visit descriptors

| Physicians      | Pre, $n$ | During, $n$ |
|-----------------|----------|-------------|
| Attending physicians | 14       | 13          |
| Fellow physicians    | 4        | 5           |
| Resident physicians  | 25       | 28          |

| Patient information for visits | Pre, $n = 1,584$ SD, % | During, $n = 1,737$ SD, % | $P$ value |
|-------------------------------|------------------------|------------------------|----------|
| Age, years                    | 50.8 14.5              | 51.5 14.1              | 0.166    |
| Gender, male, %               | 432 27%                | 463 27%                | 0.689    |
| Race                          |                        |                        |          |
| White or Caucasian, %         | 1115 70%              | 1212 70%              | 0.847    |
| Black or African American, %  | 244 15%                | 266 15%                |          |
| Other, %                      | 225 14%                | 259 15%                |          |
| Ethnicity                     |                        |                        |          |
| Not Hispanic origin, %        | 787 50%                | 858 49%                | 0.868    |
| Hispanic origin, %            | 797 50%                | 879 51%                |          |
| Preferred language            |                        |                        |          |
| English, %                    | 1095 69%              | 1188 68%              | 0.871    |
| Spanish, %                    | 417 26%                | 465 27%                |          |
| Other, %                      | 72 5%                  | 84 5%                  |          |
| Insurance                     |                        |                        |          |
| Medicaid, %                   | 621 39%                | 647 37%                | 0.353    |
| Medicare, %                   | 483 30%                | 529 30%                |          |
| Financial Assistance, %       | 258 16%                | 281 16%                |          |
| Commercial, %                 | 222 14%                | 280 16%                |          |
| Visit type                    |                        |                        | 0.016    |
| Return patient visit, %       | 1419 90%              | 1509 87%              |          |
| New patient visit, %          | 165 10%                | 228 13%                |          |

Bold value indicates statistically significant ($P < 0.05$).

### Table 2. Interventions as documented during the intervention period

| Intervention                        | Normal Clinic Flow $^a$ (n = 1152), % | Extra Calls $^b$ (n = 585), % | $P$ value |
|-------------------------------------|---------------------------------------|-------------------------------|-----------|
| Questions encouraged documented?    | 98                                    | 99                            | 0.023     |
| Teach-back communication documented?| 92                                    | 92                            | 0.877     |
| Brown-bag medication review documented? | 36                                  | 69                            | <0.001    |

$^a$Normal clinic flow: one reminder call.
$^b$Extra calls: convenience sample of patients who received an extra reminder call asking them to bring in their medications.

Bold value indicates statistically significant ($P < 0.05$).
were for bDMARDs, 95 (4%) were for gout medications, 85 (4%) were for osteoporosis medications, and 926 (40%) were for glucocorticoids.

The overall mean PDC increased 14% when comparing the preimplementation and during-implementation periods ($P < 0.001$). Mean PDCs among individual medication categories also increased significantly (Table 3), with the exception of gout-related medications ($P = 0.061$). In a preplanned subgroup analysis, which required individuals to receive the same medication during both time periods, more profound and statistically significant improvements were seen in the mean PDC (22%) and in all subdivisions of rheumatology-related medications (Figure 1).

Linear regression was performed in this subgroup of individuals who had the same prescription during both the pre- and during-implementation periods to determine the impact of the individual toolkit interventions on the change in PDC. Variables used in this analysis included questions encouraged, medication review, teach-back, age, sex, self-identified race, self-identified ethnicity, preferred language, and insurance. In this subgroup, a statistically significant improvement was observed in PDC in association with documentation of teach-back (9% improvement; $P = 0.001$). Additional variables associated with an increase in individual medication PDC, when compared with the referent, included Spanish speaking, Medicare and/or commercial insurance status, white race, and non-Hispanic ethnicity (Table 4).

**Table 3.** Overall proportion of days covered (PDC) and PDC stratified by medication category, comparing pre- and during implementation periods; unpaired (not required to have a prescription in both periods)

|                          | Pre-implementation |                         | During implementation |                         | % change | p-value |
|--------------------------|--------------------|-------------------------|-----------------------|-------------------------|----------|---------|
|                          | n =                | Mean SD                 | n =                  | Mean SD                 |          |         |
| Overall PDC              | 974                | 35% 25%                 | 1478                  | 48% 32%                 | 14%      | <0.001  |
| sDMARD                   | 438                | 40% 24%                 | 670                   | 56% 30%                 | 15%      | <0.001  |
| bDMARD                   | 132                | 37% 22%                 | 184                   | 53% 30%                 | 16%      | <0.001  |
| Gout                     | 35                 | 46% 28%                 | 70                    | 57% 31%                 | 12%      | 0.061   |
| Osteoporosis             | 27                 | 41% 20%                 | 67                    | 65% 28%                 | 24%      | <0.001  |
| Steroids                 | 342                | 25% 24%                 | 487                   | 33% 31%                 | 8%       | <0.001  |

sDMARD = synthetic disease modifying anti-rheumatic drug; bDMARD = biologic disease modifying anti-rheumatic drug

Bold values indicate statistically significant ($P < 0.05$). 

**Disease activity.** Among clinic patients with RA, 505 CDAI observations were recorded in the preimplementation period, and 696 observations were recorded during the implementation period. These observations were narrowed to a subpopulation of 217 patients with RA with CDAI observations during both periods and concurrent Denver Health pharmacy observations for sDMARD or bDMARD prescriptions. In an unadjusted analysis comparing differences in disease activity measures between the pre- and during-implementation periods, significant differences were observed in this subpopulation between the two time periods, including a decrease in the mean EGA (2.8 versus 2.2; $P = 0.005$), the
mean PGA (4.3 versus 3.5; \( P = 0.009 \)), and the mean fatigue score (4.9 versus 4.0; \( P = 0.021 \)). Non–statistically significant trends towards improvement in the mean CDAI and the mean multidimensional health assessment questionnaire score were noted (see Supplemental Table 2). In an unadjusted analysis in which we compared average CDAI values for different groups in the two time periods, the largest reduction in the CDAI was in those who were using financial assistance (unadjusted reduction in the mean CDAI of 8.2). There were non–statistically significant higher preimplementation mean CDAI values in African American, non-Hispanic, and English-speaking patients compared with referents (Supplemental Table 3).

In a further analysis of these 217 patients with RA, using GEE regression and the same variables used in the medication adherence analysis (with the addition of RA disease duration), predictors of a decrease in the CDAI included African American race and Hispanic ethnicity (Table 5).

### Table 4. Interventions’ and baseline variables’ association with change in proportion of days covered (PDC) by linear regression

| Variable                              | coef          | 95% CI       | \( P \) value |
|---------------------------------------|---------------|--------------|---------------|
| Documented questions encouraged       | -0.02         | -0.09       | 0.579         |
| Documented brown-bag performed       | 0.00          | -0.06       | 0.855         |
| Documented teach-back performed      | 0.08          | 0.04        | 0.001         |
| Age                                   | 0.00          | 0.00        | 0.842         |
| Gender, male                          | 0.02          | 0.03        | 0.469         |
| Self-identified race                  |               |             |               |
| White or Caucasian                    | REF           |             |               |
| Black or African American             | -0.11         | -0.19       | 0.008         |
| Other                                 | 0.04          | -0.02       | 0.217         |
| Self-identified ethnicity             |               |             |               |
| Not Hispanic                          | REF           |             |               |
| Hispanic origin                       | -0.16         | -0.24       | <0.001        |
| Preferred language                    |               |             |               |
| English                               | 0.12          | -0.05       | 0.001         |
| Spanish                               | 0.07          | -0.03       | 0.186         |
| Other                                 |               |             |               |
| Insurance                             |               |             |               |
| Medicaid                              | REF           |             |               |
| Medicare                              | 0.12          | 0.05        | 0.001         |
| Financial Assistance                  | 0.03          | -0.04       | 0.388         |
| Commercial                            | 0.15          | 0.06        | 0.001         |

### Table 5. Variables and interventions associated with change in clinical disease activity index (CDAI) from pre-intervention to during-intervention period, by GEE

| Variable                              | coef          | 95% CI       | \( P \) value |
|---------------------------------------|---------------|--------------|---------------|
| Documented questions encouraged       | -0.52         | -5.58       | 0.839         |
| Documented brown-bag performed       | -2.91         | -7.73       | 0.236         |
| Documented teach-back performed      | -1.29         | -6.12       | 0.602         |
| PDC difference                        | -2.88         | -9.21       | 0.373         |
| Age                                   | -0.15         | -0.33       | 0.104         |
| Gender, male                          | 1.20          | -3.51       | 0.518         |
| RA disease duration                   | -0.18         | 0.01        | 0.600         |
| Self-identified race                  |               |             |               |
| White or Caucasian                    | REF           |             |               |
| Black or African American             | -7.47         | -14.58      | 0.040         |
| Other                                 | -2.91         | -7.96       | 0.259         |
| Self-identified ethnicity             |               |             |               |
| Not Hispanic                          | REF           |             |               |
| Hispanic, Latino/a, Spanish, or Mexican origin | -7.57 | -13.60 | -1.54 | 0.014 |
| Preferred language                    |               |             |               |
| English                               | 4.42          | -1.59       | 0.149         |
| Spanish                               | -3.55         | -19.80      | 0.668         |
| Other                                 |               |             |               |
| Insurance                             |               |             |               |
| Medicaid                              | REF           |             |               |
| Medicare                              | 2.25          | -3.78       | 0.464         |
| Financial Assistance                  | 1.06          | -5.02       | 0.733         |
| Commercial                            | -1.89         | -8.85       | 0.594         |
adjusted analysis using GEE, predictors of an increase in the absolute value of EGA minus PGA, compared with referents, were African American race and Hispanic ethnicity (Supplemental Table 4). Variables used in this analysis were the same as those used in the medication adherence analysis.

Feasibility. In the preintervention period, the mean visit duration was 21.4 minutes, whereas the mean visit duration during the intervention was 20.6 minutes, with no statistically significant difference by Hotelling's $T^2$ test ($P = 0.760$), after controlling for patient visit type, trainee presence, and medical interpreter use.

DISCUSSION

The toolkit, specifically teach-back, was associated with improved medication adherence in most rheumatology patients in a safety-net academic clinic with a diverse population. Notably, PDC increased more than 20% in patients with fills for the same prescription in both time periods of the study. The toolkit did not improve patient satisfaction, the gap between PGA and EGA, or RA disease control in our overall population. However, a greater decrease in the CDAl, when compared with referents, were seen in African American and Hispanic patients. It was feasible to implement the toolkit: two of the interventions were performed at more than 90% of the visits, and the toolkit did not increase visit time.

Medication nonadherence is a major issue in the treatment of all chronic conditions, including RA (26,27). Mediocre adherence to RA therapies is estimated to be as low as 30% and is associated with suboptimal disease control (28–31). Providers often do not recognize nonadherence, and it cannot be reliably predicted by demographic factors (26). Although patient education and mobile text messages have been shown to improve medication adherence in RA (32,33), the effects of interventions to improve medication adherence in RA are inconsistent (34).

Teach-back’s dramatic impact on PDC can be explained by its ability to help patients learn more about their disease and the risks and benefits of medication therapy. These are the exact needs that have been identified as goals in recent publications in the rheumatology literature that have clarified the relationship between the intentional nonadherence of patients with RA and both their concerns about medication toxicity and the necessity of aggressive therapy (35,36). Improved patient-provider communication likely drove the PDC improvement because the toolkit does not entail other interventions to improve medication adherence such as pharmacy navigation training, regimen simplification, or medication cost control.

The toolkit’s positive impact on medication adherence in Spanish-speaking patients is an important finding given the prevalence of limited English proficiency and its negative impact on health outcomes. More than 60 million persons in the United States speak a language at home other than English (37). Limited English proficiency has been increasingly studied in RA and has been shown to be associated with increased disease activity and worse functional status, which are perhaps mediated through suboptimal shared decision-making, poor knowledge about medications, and the challenges posed by patient-reported outcome instruments (5,9,38–40).

Our finding that African American race and Hispanic ethnicity were predictive of decreases in the CDAl with the intervention is of interest given the extensive evidence of ethnic and racial disparities in RA care in the United States. Studies have shown differences in processes of care, including delayed or reduced disease-modifying antirheumatic drug or biologic therapies among minorities (41–43). This adverse pattern of effective medication use likely contributes to the increased disability, worse global health, and higher RA disability documented in these vulnerable populations (38,44).

Patients and providers often differ widely in their assessments of RA disease activity (9,45). Although the PGA and EGA improved during our intervention, a possible explanation for its failure to narrow the gap between the PGA and EGA is that it did not create the additional time and improved communication needed for the providers to better understand the patients’ perspective on disease activity and vice-versa. This goal may have been aspirational given the PGA’s poor relationship to joint inflammation (46).

This study has several limitations. The low rates of documented brown-bag medication reviews potentially limited the ability of the toolkit to exert a positive impact. These low rates likely speak to both primary nonadherence and the fragility of our patients’ medication-taking behavior. The lower rate of participation with the brown-bag medication review initiative in the patients who received regular clinic flow reminder calls only is a valuable finding in itself because most studies of brown-bag medication reviews provide information regarding the effects of reviews performed and have not reported how many persons were contacted or approached to obtain these data. The low rates of brown-bag medication reviews do not influence our conclusion that adoption of the toolkit is feasible because our feasibility study was conducted in the convenience sample of patients who received additional reminder calls. The brown-bag medication review levels documented in that subgroup are consistent with reported percentages in another urban teaching clinic (47). With our findings, we argue that rheumatology clinics caring for many vulnerable patients will need multifaceted strategies to encourage patients to participate with bringing medications in for brown-bag reviews.

Another limitation is that some of our conclusions about the impact of the intervention on patient satisfaction are hindered by our clinic’s high baseline customer service. A ceiling effect is likely present because more than half of the patient satisfaction instruments had preintervention scores above 90% (see Supplemental Table 1). Additional research regarding the toolkit is needed in settings with lower patient experience scores.

Our clinic’s low preintervention PDC may have limited the intervention’s impact on RA disease control. The sDMARD adherence improved, but adherence only reached 64.8%, which may not have
been high enough to impact the CDAI. Additionally, our EMR is unable to capture PDC data from outside pharmacies, and very low numbers of observations were seen for prescriptions filled from our pharmacy for biologic agents because many patients in safety-net clinics receive high-cost medications through medication assistance programs. The lack of accounting for these bDMARDs creates some ambiguity about our observations regarding potential relationships between PDC and the CDAI. Our medication adherence data suggest that in a public health safety-net clinic with very low baseline medication adherence, the toolkit is an intervention that may improve medication adherence but that ultimately may need to be paired with other interventions. Research into the challenges that vulnerable patients face when trying to navigate patient assistance programs for biologic agents is also needed.

Strengths of this study include the simplicity of the intervention and its real-world setting, which is a public health clinic that includes a wide range of patients in terms of sex, age, race, and ethnicity. As such, it is part of a growing research agenda that seeks to share the great strides in RA care over the past decades in affluent societies with these communities’ most vulnerable persons (6,16,42).

These findings expand what is known about strategies to improve medication adherence, reduce RA care disparities, and improve outcomes for underserved patients with LHL. Despite LHL’s high prevalence and association with adverse RA outcomes, few interventions improve the care of such patients (16,17). The toolkit’s universal deployment design also ensures that its potential benefits will not be restricted to patients with LHL. The toolkit is feasible to adopt and is able to improve medication adherence, with providers using teach-back in a real-world clinical setting.

AUTHOR CONTRIBUTIONS

Drs. Hirsh, Wood, Caplan, and Davis were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be published and take responsibility for the integrity of the data and the accuracy of the data analysis.

Study conception and design. Hirsh, Keniston, Davis.
Acquisition of data. Hirsh, Keniston, Boyle, Quinzanos, Davis.
Analysis and interpretation of data. Davis, Hirsh.

REFERENCES

1. Patient Protection and Affordable Care Act, Pub L No. 111-148, 124 Stat 119. 2010. URL: https://www.congress.gov/111/plaws/publ148/PLAW-111publ148.pdf.
2. Rudd RE. Mismatch between skills of patients and tools in use: might literacy affect diagnoses and research? [editorial]. J Rheumatol 2010;37:885–6.
3. Kutner M, Greenberg E, Jin Y, Paulsen C, White S. The health literacy of america’s adults: results from the 2003 National Assessment of Adult Literacy. 2006. URL: https://nces.ed.gov/pubsearch/pubsinfo.asp?pubid=2006483.
4. Caplan L, Wolfe F, Michaud K, Quinzanos I, Hirsh JM. Strong association of health literacy with functional status among rheumatoid arthritis patients: a cross-sectional study. Arthritis Care Res (Hoboken) 2014;66:508–14.
5. Paasche-Orlow MK, Wolf MS. The causal pathways linking health literacy to health outcomes. Am J Health Behav 31 Suppl 1:S19–26.
6. Barton JL, Trupin L, Tonner C, Imboden J, Katz P, Schillinger D, et al. English language proficiency, health literacy, and trust in physician are associated with shared decision making in rheumatoid arthritis. J Rheumatol 2014;41:1290–7.
7. Wong PK, Christie L, Johnston J, Bowling A, Freeman D, Joshua F, et al. How well do patients understand written instructions?: health literacy assessment in rural and urban rheumatology outpatients. Medicine (Baltimore) 2014;93:e129.
8. Martin RW, McCallops K, Head AJ, Eggebeen AT, Birmingham JD, Tellinghuisen DJ. Influence of patient characteristics on perceived risks and willingness to take a proposed anti-rheumatic drug. BMC Med Inform Decis Mak 2013;13:89.
9. Hirsh JM, Boyle DJ, Collier DH, Oxenfeld AJ, Caplan L. Health literacy predicts the discrepancy between patient and provider global assessments of rheumatoid arthritis activity at a public urban rheumatology clinic. J Rheumatol 2010;37:961–6.
10. Gordon MM, Hampson R, Capell HA, Madhok R. Illiteracy in rheumatoid arthritis patients as determined by the Rapid Estimate of Adult Literacy in Medicine (REALM) score. Rheumatology (Oxford) 2002;41:750–4.
11. Hirsh JM, Davis LA, Quinzanos I, Keniston A, Caplan L. Health literacy predicts discrepancies between traditional written patient assessments and verbally administered assessments in rheumatoid arthritis. J Rheumatol 2014;41:256–64.
12. Hirsh J, Wood P, Keniston A, Peng M, Ramaswami S, Caplan L, et al. Limited health literacy and patient confusion about rheumatoid arthritis patient global assessments and model disease states. Arthritis Care Res (Hoboken) 2015;71:611–9.
13. McCormack L, Thomas V, Lewis MA, Rudd R. Improving low health literacy and patient engagement: a social ecological approach. Patient Educ Couns 2017;100:8–13.
14. Petkovic J, Barton JL, Flurey C, Goel N, Bartels CM, Barnabe C, et al. Health equity considerations for developing and reporting patient-reported outcomes in clinical trials: a report from the OMERACT Equity Special Interest Group. J Rheumatol 2017;44:1727–33.
15. Petkovic J, Epstein J, Buchbinder R, Welch V, Rader T, Lydiatt A, et al. Toward ensuring health equity: readability and cultural equivalence of OMERACT patient-reported outcome measures. J Rheumatol 2015;42:2448–59.
16. Barton JL, Trupin L, Schillinger D, Evans-Young G, Imboden J, Montori VM, et al. Use of low-literacy decision aid to enhance knowledge and reduce decisional conflict among a diverse population of adults with rheumatoid arthritis: results of a pilot study. Arthritis Care Res (Hoboken) 2016;68:889–98.
17. Smith MY, Wallace LS. Reducing drug self-injection errors: a randomized trial comparing a “standard” versus “plain language” version of Patient Instructions for Use. Res Soc Adm Pharm 2013;9:621–5.
18. DeWalt DA, Broucksoiu KA, Hawk V, Brach C, Hink A, Rudd R, et al. Developing and testing the health literacy universal precautions toolkit. Nurs Outlook 2011;59:85–94.
19. Paasche-Orlow MK, Wolf MS. Evidence does not support clinical screening of literacy. J Gen Intern Med 2008;23:100–2.
20. Bass PF III, Wilson JF, Griffith CH, Barnett DR. Residents’ ability to identify patients with poor literacy skills. Acad Med 2002;77:1039–41.
21. Wolf MS, Williams MV, Parker RM, Parikh NS, Nowlan AW, Baker DW. Patients’ shame and attitudes toward discussing the results of literacy screening. J Health Commun 2007;12:721–32.
22. Callahan LF, Hawk V, Rudd R, Hackney B, Bhandari S, Prizer LP, et al. Adaptation of the health literacy universal precautions toolkit for rheumatology and cardiology: applications for pharmacy professionals to improve self-management and outcomes in patients with chronic disease. Res Social Adm Pharm 2013;9:597–608.

23. Dore A, Dye J, Hourani L, Hackney B, Criscione-Schreiber LG, Hant FN, et al. Incorporating the Health Literacy Universal Precautions Toolkit Quick Start in academic rheumatology practices: Carolina Fellows Collaborative [abstract]. Arthritis Rheum 2013:65 Suppl:S414.

24. Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005;7:R796–806.

25. Linden A. PDC: Stata module for computing the proportion of days covered (of a medication). URL: http://fmwww.bc.edu/Repeb/boccode/p/pdcado.

26. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487–97.

27. Kelly A, Tong A, Tymms K, March L, Craig JC, de Vera M, et al. Outcome Measures in Rheumatology - Interventions for medication adherence (OMERACT-Adherence) core domain set for trials of interventions for medication adherence in rheumatology: 5 phase study protocol. Trials 2015;19:204.

28. Nakagawa S, Nakaishi M, Hashimoto M, Ito H, Yamamoto W, Nakashima R, et al. Effect of medication adherence on disease activity among Japanese patients with rheumatoid arthritis. PLoS One 2018;13:e0206943.

29. Li L, Cui Y, Yin R, Chen S, Zhao Q, Chen H, et al. Medication adherence has an impact on disease activity in rheumatoid arthritis: a systematic review and meta-analysis. Patient Prefer Adherence 2017;11:1343–56.

30. Paama A, Schenk CV, Timman R, Busschbach JJV, van den Bemt BJ, Molenaar E, et al. Non-adherence to disease-modifying anti-rheumatic drugs is associated with higher disease activity in early arthritis patients in the first year of the disease. Arthritis Res Ther 2015;17:281.

31. Waimann CA, Marengo MF, de Achaval S, Cox VL, Garcia-Gonzalez A, Reveille JD, et al. Electronic monitoring of oral therapies in ethnically diverse and economically disadvantaged patients with rheumatoid arthritis: consequences of low adherence. Arthritis Rheum 2013;65:1421–9.

32. Tabeanguy N, Chaiamnuay S, Asavatanabodee P, Narongroenkavin P. Effect of patient education on medication adherence of patients with rheumatoid arthritis: a randomized controlled trial. Patient Prefer Adherence 2019;13:119–29.

33. Mary A, Boursier A, Desailly Henry I, Grados F, Sejourne A, Salomon S, et al. Mobile phone text messages and effect on treatment adherence in patients taking methotrexate for rheumatoid arthritis: a randomized pilot study. Arthritis Care Res (Hoboken) 2019;71:1344–52.

34. Galo JS, Mehat P, Rai SK, Avina-Zubieta A, de Vera MA. What are the effects of medication adherence interventions in rheumatic diseases: a systematic review. Ann Rheum Dis 2016;75:667–73.

35. McCulley C, Katz P, Trupin L, Yelin EH, Barton JL. Association of medication beliefs, self-efficacy, and adherence in a diverse cohort of adults with rheumatoid arthritis. J Rheumatol 2018;45:1636–42.

36. Kelly A, Tymms K, Tunnicliffe DJ, Sumpton D, Perera C, Fallow K, et al. Patients’ attitudes and experiences of disease-modifying anti-rheumatic drugs in rheumatoid arthritis and spondyloarthritis: a qualitative synthesis. Arthritis Care Res (Hoboken) 2018;70:52532.

37. Ryan C. Language use in the United States: 2011. Washington, DC: US Census Bureau; 2013.

38. Barton JL, Trupin L, Schillinger D, Gansky SA, Tonner C, Margarett M, et al. Racial and ethnic disparities in disease activity and function among persons with rheumatoid arthritis from university-affiliated clinics. Arthritis Care Res (Hoboken) 2011;63:1238–46.

39. Barton JL, Schmajuk G, Trupin L, Graf J, Imboden J, Yelin E, et al. Poor knowledge of methotrexate associated with older age and limited English-language proficiency in a diverse rheumatoid arthritis cohort. Arthritis Res Ther 2013;15:R157.

40. Izadi Z, Katz PP, Schmajuk G, Gandrup J, Li J, Gianfrancesco M, et al. Effects of language, insurance and race/ethnicity on measurement properties of the PROMIS Physical Function Short Form 10a in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2019;71:925–35.

41. Schmajuk G, Trivedi AN, Solomon DH, Yelin E, Trupin L, Chakravarty EF, et al. Receipt of disease-modifying antirheumatic drugs among patients with rheumatoid arthritis in Medicare managed care plans. JAMA 2011;305:480–6.

42. Suarez-Almazor ME, Berrios-Rivera JP, Cox V, Janssen NM, Marcus DM, Sesmons S. Initiation of disease-modifying antirheumatic drug therapy in minority and disadvantaged patients with rheumatoid arthritis. J Rheumatol 2009;34:2400–7.

43. Kim SC, Yelin E, Tonner C, Solomon DH. Changes in use of disease-modifying antirheumatic drugs for rheumatoid arthritis in the United States during 1983-2009. Arthritis Care Res (Hoboken) 2013;65:1529–33.

44. Bruce B, Fries JF, Murtagh KN. Health status disparities in ethnic minority patients with rheumatoid arthritis: a cross-sectional study. J Rheumatol 2007;34:1475–9.

45. Barton JL, Imboden J, Graf J, Glidden D, Yelin EH, Schillinger D. Patient-physician discordance in assessments of global disease severity in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2010;62:857–64.

46. Ferreira RJ, Carvalho PD, Ndosi M, Duarte C, Chopra A, Murphy E, et al. Impact of patient’s global assessment on achieving remission in patients with rheumatoid arthritis: a multinational study using the METEOR database. Arthritis Care Res (Hoboken) 2019;71:1317–25.

47. Weiss BD, Brega AG, LeBlanc WG, Mabachi NM, Barnard J, Albright K, et al. Improving the effectiveness of medication review: guidance from the Health Literacy Universal Precautions Toolkit. J Am Board Fam Med 2016;29:18–23.